piclidenoson
Phase 3Small molecule
piclidenoson is one of 44 small molecule programs targeting Psoriasis. It is currently in Phase 3.
2
Indications
3
Total Trials
2
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1piclidenoson
CCan-Fite BioPharma
Phase 3
Stivarga
BayerPreclinical
Aimovig
AmgenPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Angiomax
BBaxter Healthcare Corporation
Preclinical
DAS181
AAnsun Biopharma, Inc.
Preclinical
Tpa
UUniversity of Florida
Preclinical
Dornase Alfa Inhalant Product
UUniversity Hospital, Strasbourg, France
Preclinical
Thrombolytic
FFaculty Hospital Kralovske Vinohrady
Preclinical
Mesenchymal Stem Cell Therapy
FFundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Psoriasis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for piclidenoson. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- CCan-Fite BioPharma